

PRECEPTORSHIP PROGRAMME

Gastrointestinal Tumours

Multidisciplinary management,
standards of care and future perspectives

SINGAPORE

19-21 NOVEMBER 2019

Co-Chairs

Andrés Cervantes, ES
Matthew C. H. Ng, SG

ESMO PRECEPTORSHIP PROGRAMME GASTROINTESTINAL TUMOURS

Multidisciplinary management, standards of care and future perspectives

Singapore
19-21 November 2019

CO-CHAIRS:

Andrés Cervantes, Spain
Matthew C. H. Ng, Singapore

SPEAKERS:

Chung Yip Chan, Singapore	Brigette Ma, Hong Kong
Ian Chau, United Kingdom	Joanne Y. Y. Ngeow, Singapore
Su Pin Choo, Singapore	Sun Young Rha, South Korea
Fortunato Ciardiello, Italy	David Tai, Singapore
Robert Glynne-Jones, United Kingdom	Thomas Yau, Hong Kong
Claus-Henning Koehne, Germany	Wei Peng Yong, Singapore
Tony K. H. Lim, Singapore	

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology and histoprognostic factors
- To learn about the management of patients after progression, in special situations and side effects of treatments
- To learn about the management of unresectable/relapsing hepatocellular carcinoma (HCC) and new approaches after failure of first-line treatment
- To review the standard of care of anal carcinomas
- To learn the fundamental of epidemiology, aetiology, pathogenesis, molecular events and ethnic patterns as contributing factors to heterogeneity in gastric cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment in gastric cancer
- To learn about the advances in the treatment and novel targets in gastric cancer

ACCREDITATION

The programme of this event has been accredited with **13 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Tuesday, 19 November 2019

09:00-09:15 15'	Welcome and introduction	Andrés Cervantes, ES Matthew C. H. Ng, SG
09:15-11:15 120'	SESSION 1 Early colorectal cancer	Chair: Ian Chau, UK
40'	What pathology can tell us in the approach of localized colorectal cancer	Tony K. H. Lim, SG
30'	Adjuvant treatment for colon cancer	Andrés Cervantes, ES
30'	State-of-the-art: Standard of care for resectable locally advanced rectal cancer	Robert Glynne-Jones, UK
20'	The role of adjuvant chemotherapy in localized rectal cancer	Ian Chau, UK
11:15-11:35 Coffee break		
11:35-12:20 45'	SESSION 1 - cont. Early colorectal cancer	Chair: Andrés Cervantes, ES
30'	Participants clinical case discussion (3x10')	Faculty
15'	Discussion	Faculty
12:20-13:20 Lunch		
13:20-16:35 165'	SESSION 2 Metastatic colorectal cancer: Liver limited metastases	Chair: Brigette Ma, HK
30'	Review of the ESMO consensus conference on metastatic colorectal cancer	Fortunato Ciardiello, IT
30'	Unresectable or borderline resectable chemotherapy +/- targeted agents	Claus-Henning Koehne, DE
15'	How to integrate surgery in the management of potentially borderline resectable patients	Chung Yip Chan, SG
45'	Optimal sequencing of chemotherapy and targeted agents in metastatic colorectal cancer	Brigette Ma, HK
15:20-15:50 Coffee break		
30'	Participants clinical case discussion (3x10')	Faculty
15'	Discussion	Faculty

Wednesday, 20 November 2019

08:30-09:00 30'	SESSION 3 Cancer genetics	Chair: Joanne Y. Y. Ngeow, SG
30'	A practical approach to hereditary GI cancers	Joanne Y. Y. Ngeow, SG
09:00-10:10 70'	SESSION 4 Pancreatic and biliary tract cancer	Chair: Brigette Ma, HK
40'	Medical treatment for pancreatic cancer: localized, locally advanced and metastatic	Fortunato Ciardiello, IT
30'	Management of biliary tract cancer	David Tai, SG
10:10-10:30 Coffee break		

10:30-11:55 85'	SESSION 5 Hepatocellular carcinoma (HCC)	Chair: Su Pin Choo, SG
20'	Management of intermediate HCC	Su Pin Choo, SG
20'	Update on medical treatment for unresectable HCC	Thomas Yau, HK
30'	Participants clinical case discussion (3x10')	Faculty
15'	Discussion	Faculty
11:55-12:25 30'	SESSION 6 Anal tumours	Chair: Su Pin Choo, SG
30'	Standard of care for anal squamous carcinomas	Robert Glynne-Jones, UK
12:25-13:30	Lunch	
13:30-16:15 140'	SESSION 7 Epidemiology and treatment of gastroesophageal cancer	Chair: Matthew C. H. Ng
15'	Epidemiology (including GE junction) and clinical presentation	Wei Peng Yong, SG
40'	Squamous cell carcinoma of the esophagus: Strategies for pre-operative management and metastatic disease	Matthew C. H. Ng, SG
40'	Neo- and adjuvant treatment for gastroesophageal adenocarcinoma	Andrés Cervantes, ES
15:05-15:30	Coffee break	
30'	Participants clinical case discussion (3x10')	Faculty
15'	Discussion	Faculty
19:30	Dinner	

Thursday, 21 November 2019

09:00-11:45 135'	SESSION 8 Advanced disease for gastroesophageal cancer	Chair: Sun Young Rha, KR
30'	Chemotherapy for metastatic disease	Sun Young Rha, KR
30'	Biological targeted agents	Sun Young Rha, KR
30'	Immunotherapy for advanced oesophago-gastric cancer	Ian Chau, UK
10:30-11:00	Coffee break	
30'	Participants clinical case discussion (3x10')	Faculty
15'	Discussion	Faculty
11:45-12:00 15'	Conclusion and farewell	Andrés Cervantes, ES Matthew C. H. Ng, SG
12:00-13:00	Lunch	

Note: Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion